Jim Simons Viking Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 159,400 shares of VKTX stock, worth $10.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

159,400

Holding current value

$10.6 Million

% of portfolio

0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$47.39 - $80.2 $7.55 Million - $12.8 Million	159,400 New	159,400 $8.45 Million
Q2 2023 Aug 11, 2023	SELL	$14.84 - $24.79 $10.5 Million - $17.5 Million	-704,200 Reduced 92.51%	57,000 $924,000
Q1 2023 May 12, 2023	SELL	$8.08 - $17.33 $1.53 Million - $3.28 Million	-189,400 Reduced 19.92%	761,200 $12.7 Million
Q4 2022 Feb 13, 2023	SELL	$2.72 - $9.4 $260,576 - $900,520	-95,800 Reduced 9.16%	950,600 $8.94 Million
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $459,509 - $700,978	180,200 Added 20.8%	1,046,400 $2.85 Million
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $213,424 - $318,619	-101,149 Reduced 10.46%	866,200 $2.5 Million
Q1 2022 May 13, 2022	BUY	$3.0 - $4.88 $2.17 Million - $3.54 Million	724,476 Added 298.29%	967,349 $2.9 Million
Q4 2021 Feb 11, 2022	BUY	$4.6 - $6.72 $1.12 Million - $1.63 Million	242,873 New	242,873 $1.12 Million
Q1 2021 May 13, 2021	SELL	$5.74 - $9.67 $1.03 Million - $1.73 Million	-179,000 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$5.3 - $6.71 $752,070 - $952,149	141,900 Added 382.48%	179,000 $1.01 Million
Q3 2020 Nov 13, 2020	BUY	$5.73 - $8.11 $212,583 - $300,881	37,100 New	37,100 $216,000

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.12B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account